Praxis Precision Medicines Future Growth
Future criteria checks 2/6
Praxis Precision Medicines is forecast to grow earnings and revenue by 9.9% and 81.1% per annum respectively while EPS is expected to grow by 17.7% per annum.
Key information
9.9%
Earnings growth rate
17.7%
EPS growth rate
| Biotechs earnings growth | 28.0% |
| Revenue growth rate | 81.1% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Oct 13We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Aug 30
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
May 14Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing
Mar 26Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?
Feb 27Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Nov 29Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Aug 14Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?
Feb 10Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely
Oct 21Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02
Aug 08Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
Jun 10We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
May 15Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Jan 27Praxis Precision Medicines: Genetic Medicines For Neurological Disease
Nov 23We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate
Oct 14Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
Apr 30Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth
Mar 12Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares
Jan 18Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.
Jan 07Praxis Precision Medicine plummets 27% on clinical hold on lead drug
Nov 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 32 | -256 | -130 | -117 | 8 |
| 12/31/2025 | 1 | -237 | -193 | -171 | 10 |
| 12/31/2024 | 1 | -182 | -298 | -128 | 10 |
| 9/30/2024 | 2 | -151 | -100 | -99 | N/A |
| 6/30/2024 | 2 | -124 | -95 | -95 | N/A |
| 3/31/2024 | 2 | -125 | -99 | -99 | N/A |
| 12/31/2023 | 2 | -123 | -111 | -111 | N/A |
| 9/30/2023 | 2 | -138 | -116 | -116 | N/A |
| 6/30/2023 | 1 | -157 | -138 | -138 | N/A |
| 3/31/2023 | 1 | -183 | -164 | -164 | N/A |
| 12/31/2022 | N/A | -214 | -185 | -185 | N/A |
| 9/30/2022 | N/A | -231 | -202 | -201 | N/A |
| 6/30/2022 | N/A | -232 | -182 | -180 | N/A |
| 3/31/2022 | N/A | -208 | -154 | -153 | N/A |
| 12/31/2021 | N/A | -167 | -126 | -125 | N/A |
| 9/30/2021 | N/A | -135 | -100 | -100 | N/A |
| 6/30/2021 | N/A | -111 | -90 | -90 | N/A |
| 3/31/2021 | N/A | -88 | -70 | -70 | N/A |
| 12/31/2020 | N/A | -70 | -53 | -53 | N/A |
| 9/30/2020 | N/A | -53 | -42 | -42 | N/A |
| 6/30/2020 | N/A | -44 | -36 | -36 | N/A |
| 3/31/2020 | N/A | -41 | -34 | -34 | N/A |
| 12/31/2019 | N/A | -41 | -34 | -33 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRAX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRAX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRAX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRAX's revenue (81.1% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: PRAX's revenue (81.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRAX's Return on Equity is forecast to be high in 3 years time